Anti-SARS-CoV QuantiVac ELISA (IgG)
• - Quantitative ELISA for the determination of the concentration of IgG antibodies against the S1 antigen (including RBD) of SARS-CoV-2 in a broad linear range (using a 6-point calibration curve)
• - Excellent correlation with the WHO reference material “First WHO International Standard for anti-SARS-CoV-2 immunoglobulin” (NIBSC code: 20/136) – enables issuing of results in standardised units
• - Very good agreement of results in comparison with different neutralisation tests
• - Validated for serum, plasma and dried capillary blood as sample material
• - Fully automatable
Anti-SARS-CoV-2 ELISA (IgG or IgA)
• - Detection of anti-SARS-CoV-2 IgG or IgA antibodies using spike protein domain S1
• - Antigen includes the receptor binding domain, which is the main target of neutralising antibodies
• - Validated for serum, plasma and dried capillary blood (IgG only) as sample material
• - Fully automatable
Anti-SARS-CoV-2 NCP ELISA (IgG or IgM)
• - Detection of anti-SARS-CoV-2 IgG or IgM antibodies using modified nucleocapsid protein containing only diagnostically relevant epitopes
• - Antigen with the strongest immune dominance in the coronavirus family
• - Validated for serum, plasma and dried capillary blood (IgG only) as sample material
• - Fully automatable